AVI 6002

Drug Profile

AVI 6002

Alternative Names: AVI-6002; AVI-7357/AVI-7539; AVI-7539/AVI-7357

Latest Information Update: 09 Oct 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AVI BioPharma; United States Army Medical Research Institute of Infectious Diseases
  • Developer Sarepta Therapeutics; United States Army Medical Research Institute of Infectious Diseases
  • Class Antisense elements; Antisense oligonucleotides; Antivirals
  • Mechanism of Action RNA interference; Viral RNA inhibitors; VP35 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ebola virus infections

Most Recent Events

  • 02 Oct 2012 Discontinued - Phase-I for Ebola virus infections in USA (IV)
  • 02 Aug 2012 Suspended - Phase-I for Ebola virus infections in USA (IV)
  • 12 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top